AIM
GNMK

Aigen Investment Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Aigen Investment Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,970
Closed -$255K – 1190
2020
Q3 		$255K Buy
+17,970
New +$275K 0.03% 585
2020
Q1 		– Sell
-3,726
Closed -$18K – 1686
2019
Q4 		$18K Buy
+3,726
New +$20.6K ﹤0.01% 923

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aigen Investment Management's GNMK Position: Q4 2020 in Review

Aigen Investment Management sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2020, closing a stake of 17,970 shares — an estimated $255K sold.

Aigen Investment Management first reported a position in GNMK in Q4 2019 and held it in 2 quarters. The position peaked at $255K in Q3 2020. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

  • Aigen Investment Management reported no remaining GenMark Diagnostics, Inc position as of Q4 2020 after selling out during the quarter.
  • Aigen Investment Management sold 17,970 GenMark Diagnostics, Inc shares in Q4 2020, an estimated $255K.
  • Aigen Investment Management first reported a position in GenMark Diagnostics, Inc in Q4 2019 and held it in 2 quarters.
  • Aigen Investment Management's GenMark Diagnostics, Inc position peaked at $255K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on Aigen Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.